← Back to Search

Artificial Intelligence

Algorithm-driven for Pulmonary Embolism (ASCENT Trial)

N/A

Waitlist Available

Led By Jun Li, MD

Research Sponsored by University Hospitals Cleveland Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 30 days, 90 days

Awards & highlights

ASCENT Trial Summary

This trial aims to study the use of an artificial intelligence program to identify patients at high risk of pulmonary embolism. The goal is to determine if this AI program can help in deciding which patients need

Who is the study for?

This trial is for patients with pulmonary embolism, a condition where blood clots block the lungs' arteries. It's designed to help those who might benefit from quick and aggressive treatment. Details on specific inclusion or exclusion criteria are not provided.Check my eligibility

What is being tested?

The study tests an AI program called Aidoc that decides which patients need urgent care for their pulmonary embolism. It compares outcomes of patients selected by AI for immediate action versus traditional methods.See study design

What are the potential side effects?

Since this trial involves decision-making rather than medication, there are no direct side effects from interventions like drugs or surgery. However, indirect effects may arise from any subsequent treatments chosen as a result of the AI recommendations.

ASCENT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 30 days, 90 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 30 days, 90 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 30 days, 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Time-to-activation

Secondary outcome measures

6-minute walk test (6MWT)

Change in quality of life as measured by PEmb QoL

Length of stay

ASCENT Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Algorithm-drivenExperimental Treatment1 Intervention

Group II: PERT-drivenActive Control1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University Hospitals Cleveland Medical CenterLead Sponsor

318 Previous Clinical Trials

339,695 Total Patients Enrolled

Jun Li, MDPrincipal InvestigatorUniversity Hospitals

12 Previous Clinical Trials

1,498 Total Patients Enrolled

1 Trials studying Pulmonary Embolism

120 Patients Enrolled for Pulmonary Embolism

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the eligibility criteria for participation in this clinical study?

"Individuals aged between 18 and 99 years old with a confirmed diagnosis of pulmonary embolism are eligible for enrollment in this study, which aims to recruit approximately 390 participants."

Answered by AI

Are there any vacancies available for patients to participate in this trial?

"As per the details found on clinicaltrials.gov, recruitment for this investigation is currently inactive. The trial was initially listed on 3/1/2024 and last revised on 1/29/2024. While enrollment is presently closed, there are a total of 89 other ongoing trials actively seeking participants."

Answered by AI

Are individuals older than 45 years being sought for enrollment in this investigation?

"To be considered for this research study, individuals between the ages of 18 and 99 are encouraged to apply. It is worth noting that there are separate studies available for those under 18 years old (5 studies) as well as patients over the age of 65 (88 studies)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Artificial Intelligence to StrategiCally Enhance Pulmonary Embolism Response Team Activation

Jun Li 2024. "Artificial Intelligence to StrategiCally Enhance Pulmonary Embolism Response Team Activation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06246045.

All > Pulmonary Embolism